Impax Laboratories (NASDAQ:IPXL) is a Zacks Rank #1 (Strong Buy), and as such, we know that earnings estimates are moving higher. Let’s take …
In a research report issued today, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on shares of Lannett Company (LCI) and $45 price target. The report follows Tuesday’s news …
